In the ever-evolving landscape of healthcare, wearable technology has emerged as a game-changer. From the early days of the Holter monitor to today’s sophisticated wearable health trackers these devices have transformed how we monitor and manage health. As technology advances, the line between consumer wellness products and clinical-grade devices is becoming increasingly blurred, raising important questions about regulation, accuracy, and integration into medical practice.
The journey of wearable health technology began with the Holter monitor a portable electrocardiogram developed in the 1960s. This device allowed for continuous heart monitoring outside of clinical settings, addressing the limitations of short, in-clinic ECG readings. Today, wearable technology has expanded to include a wide range of devices, from Fitbit and Apple Watch to specialized continuous glucose monitors like Dexcom’s Stelo. These devices are not only tracking fitness metrics but also providing insights into vital health parameters.
Blurring the Lines Between Consumer and Clinical Devices
The market for wearable health technology has diverged into two main categories: medical-grade devices designed for clinical use and consumer wellness products aimed at general health monitoring. However, recent advancements are blurring these distinctions. For instance, Dexcom’s Stelo the first over-the-counter continuous glucose monitor cleared by the Food and Drug Administration (FDA) brings a traditionally prescription-based device to direct consumer use. Similarly, Apple’s HealthKit framework aggregates health records and wearable data, integrating consumer-generated information with clinical data.
Companies like WHOOP are also bridging the gap by integrating wearable metrics with clinical blood testing through partnerships with labs such as Quest Diagnostics. As consumer-generated health data begins to resemble clinically measured biomarkers, the medical community must develop standards for determining when these signals are accurate, interpretable, and useful enough to guide care. This shift is particularly important for physicians specializing in laboratory medicine, who recognize the prognostic value of these devices as they become more integrated into clinical practice.
Regulatory Changes and the Future of Wearable Technology
In response to the rapid advancements in wearable technology, regulatory bodies are updating their guidelines to accommodate these innovations. At the Consumer Technology Association’s CES show in January 2026, then FDA Commissioner Marty Makary announced updates to the agency’s guidance governing oversight of wearable technologies and AI-enabled devices. These changes aim to accelerate the speed to market for digital health devices while ensuring patient safety.
The FDA and the Centers for Medicare & Medicaid Services (CMS) are piloting programs like access and TEMPO to allow insurance reimbursement for wearables designed to improve health for people with conditions such as high blood pressure, diabetes, and depression. These initiatives enable select digital health devices to be distributed while companies collect real-world data, bypassing the traditional regulatory pathway required for medical-grade devices.
Additionally, the federal government’s Advanced Research Projects Agency for Health (ARPA-H) launched the Delphi program to develop low-cost wearable and ingestible biosensors. These devices aim to continuously track biological signals that are more challenging to measure, including hormones, immune markers, and therapeutic drug levels. These developments are encouraging, as wearables can provide a lifeline for patients by making invisible physiology visible in everyday life.
Challenges and Considerations
Despite the promising advancements, there are challenges in integrating wearable data into clinical practice. Historically, diagnostic medicine has been governed by a clear validation framework, with hospital laboratories regulated under the federal Clinical Laboratory Improvement Amendments (CLIA). However, applying this framework to consumer wearables is more complex, as many depend on proprietary algorithms and report composite wellness scores rather than levels of conventional clinical biomarkers.
For example, readiness or sleep scores may reflect physiological inputs such as heart-rate variability, body temperature, and sleep duration, but each company can weight these signals differently without tracking them to an independent predictor of a pathologic condition. Sleep trackers are largely reliable for detecting sleeping and morning wake time but are less accurate for determining stages of sleep. Data like heart-rate variability may differ between sleep trackers and do not correlate to any particular condition, making it difficult for clinicians to use these metrics diagnostically.
Artificial intelligence adds another layer of complexity. The FDA has released a discussion paper on how it might regulate generative artificial intelligence in medical devices, opening a public comment period. The paper poses questions covering risk assessment, premarket evaluation, and postmarket monitoring, highlighting the unique challenges posed by AI-enabled devices. The FDA is considering a competency-based approach to premarket evaluation, inspired by how physicians are evaluated, to assess whether a system demonstrates competence across the range of situations it will encounter.
As wearable technology continues to evolve, it is crucial to address these challenges and develop robust standards for accuracy, interpretation, and integration into clinical practice. By doing so, we can harness the full potential of wearable health devices to improve patient outcomes and transform healthcare.
